Investigational drug · Phase 3
Atebimetinib
Also called: IMM-1-104, Group A
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous).
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
2
Any phase or sponsor naming "Atebimetinib"
First trial start
2022
Oct 31, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Atebimetinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pancreatic Adenocarcinoma
- Advanced Solid Tumor
- Malignant Melanoma (Cutaneous)
- Non-small Cell Lung Cancer (NSCLC)
- Pancreatic Cancer
- Pancreatic Cancer Metastatic
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Adenocarcinoma Metastatic
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Melanoma · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Atebimetinib" as an intervention, largest first.
- Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaPivotal-lookingRecruiting
Immuneering CorporationIndustry
NCT07562152 · 570 participants (planned) · Start Jun 5, 2026 · Primary completion Jun 2028
Drug: Atebimetinib; GnP and 1 more · For: Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC and 5 more
Sites: Huntsville, Alabama; Phoenix, Arizona; Duarte, California · 76 sites in all
- Phase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebimetinib in Participants With Advanced or Metastatic NSCLC.Not yet recruiting
Immuneering CorporationIndustry
NCT07946848 · 100 participants (planned) · Start Dec 2026 · Primary completion May 2029
Drug: Atebimetinib; Cemiplimab and 2 more · For: NSCLC (Advanced Non-small Cell Lung Cancer); Non-Squamous Non Small Cell Lung Cancer; Metastatic Non-Small Lung Cell Cancer and 2 more
Sites: Fairfax, Virginia
Newest research
PubMed records naming it or its code names, newest first.
- Hemodynamic effects of ventilating or not, during cardiopulmonary bypass in a porcine model.
Kvalheim VL, Mongstad A, Husby P, et al. · Scand Cardiovasc J 2027
- Prepackaged Low-Residue Diet "Clear-Through" Reduces the Required Volume of Polyethylene Glycol Solution for Colonoscopy Preparation: An Exploratory Randomized Controlled Study.
Iida T, Kimoto Y, Yamabe E, et al. · DEN Open 2027
- Transient neurobehavioral dysfunction secondary to oxygen induced convulsion is not related to cerebral blood flow reduction.
Li C, Wang K, Zheng H, et al. · Behav Brain Res 2027
- Community-acquired pneumonia in Europe: heterogeneity, evidence gaps, and priorities for care.
Martin-Loeches I, Torres A · Lancet Reg Health Eur 2027
- Second-Stage Urethroplasty With Simultaneous Penoscrotal Transposition Correction in Proximal Hypospadias: Outcomes of a Modified Byars Two-Stage Strategy.
Wang G, Zhou L, Wang C, et al. · Andrology 2027
- Timing of cranial radiotherapy in HER2-positive breast Cancer brain metastases treated with Pyrotinib: a multicentre real-world cohort study.
Chen Z, Jing H, Huang S, et al. · Clin Transl Radiat Oncol 2027
Also in development for Pancreatic Adenocarcinoma
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
- GEMPhase 35 trials
Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer
- zoldonrasibPhase 34 trials
Revolution Medicines, Inc. · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC
- BL-8040Phase 32 trials
BioLineRx, Ltd. · Multiple Myeloma, Pancreatic Adenocarcinoma
- CF102NamodenosonPhase 32 trials
Can-Fite BioPharma · Pancreatic Adenocarcinoma, Pancreatic Cancer, Hepatocellular Carcinoma
- AB928Etrumadenant, ETRUMAPhase 24 trials
Arcus Biosciences, Inc. · Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
- ImzokitugBMS-986340Phase 22 trials
Bristol Myers Squibb · Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC), Cervical Cancer
- SelicrelumabPhase 22 trials
Roche (Genentech) · Metastatic Breast Cancer, Pancreatic Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.